The Environmental Protection Agency is taking a significant step toward potentially regulating microplastics and pharmaceuticals in drinking water for the first time. The agency plans to add these substances to its draft Contaminant Candidate List, a mandatory precursor to establishing enforceable federal limits under the Safe Drinking Water Act.
A Political Move Amid Health Concerns
The Trump administration is framing this action as a direct response to the Make America Healthy Again (MAHA) movement, a coalition of voters skeptical of chemical and pharmaceutical industry influence. This move represents an attempt to mend fences with a constituency that has previously criticized the administration's environmental and health policies, including circulating a petition calling for EPA Administrator Lee Zeldin's removal over perceived pro-industry decisions.
Zeldin is scheduled to formally announce the proposal alongside Health and Human Services Secretary Robert F. Kennedy Jr., a prominent MAHA figure. In a statement first obtained by The Hill, Zeldin declared: "For too long, Americans have vocalized concerns about plastics and pharmaceuticals in their drinking water. That ends today. By placing microplastics and pharmaceuticals on the Contaminant Candidate List for the first time ever, EPA is sending a clear message: we will follow the science, we will pursue answers, and we will hold ourselves to the highest standards to protect the health of every American family."
Scientific Basis and Regulatory Pathway
The scientific rationale for examining these contaminants is growing. A 2023 literature review indicates microplastics can impact human digestive, respiratory, endocrine, reproductive, and immune systems. The EPA notes that while pharmaceutical research continues, some compounds can bioaccumulate in humans, potentially leading to breast cancer, decreased fertility, and increased antibiotic-resistant bacteria.
Under the Safe Drinking Water Act, the EPA must publish a list of unregulated contaminants every five years that are known or anticipated to appear in public water systems. Inclusion on this list triggers a mandatory review process that can culminate in national drinking water standards, which would require water utilities to install filtration systems to remove these substances from household taps.
Forever Chemicals and Pharmaceutical Benchmarks
The agency is also advancing its approach to "forever chemicals" (PFAS) by proposing to list them as an entire chemical class rather than regulating individual compounds piecemeal. While the Biden administration previously mandated filtration for six specific PFAS compounds by 2029, the Trump administration has proposed scaling this back to just two chemicals with a delayed 2031 deadline—a decision that has contributed to tension with the MAHA movement.
Concurrently, the EPA is releasing non-enforceable human health benchmarks for 374 pharmaceuticals. These guidelines aim to provide states, tribes, and local water systems with additional information for voluntary monitoring and management, reflecting the administration's preference for guidance over regulation in some areas, similar to its approach in other policy domains like offshore energy oversight.
Broader Political Context
This regulatory maneuver occurs within a complex political landscape. The administration is attempting to balance demands from health-focused voters against its broader deregulatory agenda and support for industry. Zeldin has indicated he will pursue a "MAHA agenda" that builds on initiatives like lead pipe replacement and may address plastics more comprehensively.
The proposal represents a notable shift in the administration's public health positioning, coming after multiple decisions perceived as favorable to chemical manufacturers. It also contrasts with other administration priorities, such as repeated attempts to terminate the Low-Income Home Energy Assistance Program, detailed in our coverage of the administration's latest budget proposal.
As the EPA moves forward, the inclusion of microplastics and pharmaceuticals on the candidate list marks the beginning of a multi-year scientific assessment. The ultimate decision to regulate—and how stringently—will depend on evolving research, cost-benefit analyses, and continued political pressure from both public health advocates and industry stakeholders navigating an administration known for its unconventional approach to executive power.
